---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-001496"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:42:08.891562+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront

## Summary
- Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).
- Cash & equivalents $10.9M at Dec 31, 2022; raised ~$8.0M net in Feb 2023 offering.
- Heska agreement: $10M upfront received, up to $18M milestones; IDEXX launched Nu.Q Vet test.
- Nu.Q NETs CE marked; FDA Breakthrough Device application expected H1 2023.
- 34 patent families, 97 granted patents; capital market day set for May 11, 2023.

## SEC filing metadata
- accession: 0001477932-23-001496
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/0001477932-23-001496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-001496
- JSON: https://secwatch.observer/filing/0001477932-23-001496.json
- Plain text: https://secwatch.observer/filing/0001477932-23-001496.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported the full fiscal year ended December 31, 2022 results: revenue approximately $300,000.
  - Period: the full fiscal year ended December 31, 2022
  - Revenue: approximately $300,000
  - Result: reported results
  source text: $8.0 million in net cash (before deducting offering expenses payable by Volition) through an underwritten public offering of its common stock. · Recorded approximately $300,000 in revenue in 2022, up 240% over the prior year. · Received a $10 million upfront payment on signing the Heska Licensing and Supply Agreement. · During 2022, strengthened its
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793223001496/0001477932-23-001496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.